Auditors question future of two tissue engineering firms
This article was originally published in Clinica
Separate auditors have raised concerns over the ability of two rival tissue engineering companies to remain as going concerns. Both Organogenesis and Ortec International are taking steps to try to resolve their current situation.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.